Corpus overview


MeSH Disease

Human Phenotype


There are no transmission terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page

    IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases MESHD with tissue inflammation MESHD

    Authors: Lorien Shakib; Sara Shanaj; Aparna Nathan; - Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus; Laura T. Donlin

    doi:10.1101/2020.08.05.238360 Date: 2020-08-05 Source: bioRxiv

    Immunosuppressive and anti-cytokine treatment may have a protective effect for patients with COVID-19. Understanding the immune cell states shared between COVID-19 and other inflammatory diseases MESHD with established therapies may help nominate immunomodulatory therapies. Using an integrative strategy, we built a reference by meta-analyzing > 300,000 immune cells from COVID-19 and 5 inflammatory diseases MESHD including rheumatoid arthritis MESHD rheumatoid arthritis HP (RA), Crohns disease MESHD (CD), ulcerative colitis MESHD ulcerative colitis HP (UC), lupus, and interstitial lung disease MESHD. Our cross- disease MESHD analysis revealed that an FCN1+ inflammatory macrophage state is common to COVID-19 bronchoalveolar lavage samples, RA synovium, CD ileum, and UC colon. We also observed that a CXCL10+ CCL2+ inflammatory macrophage state is abundant in severe COVID-19, inflamed CD and RA, and expresses inflammatory genes such as GBP1, STAT1, and IL1B. We found that the CXCL10+ CCL2+ macrophages are transcriptionally similar to blood SERO-derived macrophages stimulated with TNF- and IFN-{gamma} ex vivo. Our findings suggest that IFN-{gamma}, alongside TNF-, might be a key driver of this abundant inflammatory macrophage phenotype in severe COVID-19 and other inflammatory diseases MESHD, which may be targeted by existing immunomodulatory therapies.

    Serum SERO surfactant protein A and D may be novel biomarkers of COVID-19 pneumonia MESHD pneumonia HP severity

    Authors: Atsushi Saito; KOJI KURONUMA; Keigo Moniwa; Kentaro Kodama; Satoshi Takahashi; Hiroki Takahashi; Hirofumi Chiba

    doi:10.21203/ Date: 2020-05-18 Source: ResearchSquare

    Background: COVID-19 is currently undergoing a pandemic worldwide, including in Japan, and many lives have been lost. So, there is an urgent need to develop new biomarkers for estimating progression or prognosis of COVID-19 patient. Lung-specific serum SERO biomarkers, SP-A, SP-D and KL-6 have been used clinically for diagnosis of interstitial lung disease MESHD (ILDs), but their use in COVID-19 has not been investigated. To determine whether serum SERO levels of SP-A, SP-D and KL-6 correlate with the severity of COVID-19 as indicated by clinical symptoms and radiological findings. Methods: In a cohort of 46 consecutive COVID-19 patients, laboratory data including serum SERO SP-A, SP-D and KL-6 concentrations of 82 blood SERO samples were analyzed and compared between severe and non-severe cases. In addition, the disease MESHD severity as indicated by these markers and chest HRCT images were compared.Results: Serum SERO SP-A was significantly elevated from the early stage of pneumonia MESHD pneumonia HP. In addition, serum SERO SP-A and SP-D were significantly higher in severe than in non-severe cases. KL-6 was also significantly higher in severe-cases, but its mean was below the cut-off level for ILDs. AUC and their cut-off levels to detect severe cases in patients with COVID-19 infection MESHD were 0.796 for 94.9 ng/ml of SP-A, 0.827 for 116 ng/ml of SP-D and 0.640 for 275 U/ml of KL-6. HRCT image severity scores showed moderate correlations with SP-A (ρ=0.5996, p<0.001), SP-D (ρ=0.6268, p<0.001), and weak with KL-6 (ρ=0.3489, p<0.001). In the typical course of patients whose pneumonia MESHD pneumonia HP worsened from non-severe to severe, the serum SERO SP-A and SP-D levels increased nearly in parallel with clinical findings and HRCT images.Conclusions: Lung-specific serum SERO SP-A and SP-D level increased with symptom and radiological findings. These elevations can be detected from relatively early pneumonia MESHD pneumonia HP. These results indicated that these might become a novel biomarker in COVID-19 pneumonia MESHD pneumonia HP.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.